Kim Sablich - 01 Mar 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2023, 19:50:03 UTC
Prior SEC filing: 08 Jun 2022
Next SEC filing: 07 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Kim Sablich

Key filing fact

Kim Sablich filed Form 4 for Eiger BioPharmaceuticals, Inc. on 03 Mar 2023.

Key facts

This page summarizes Kim Sablich's Form 4 filing for Eiger BioPharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2023, 19:50.

Change

Previous filing in this sequence was filed on 08 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EIGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +28,000
Change %
Price: $0.000000
Shares after: 28,000
Date: 01 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,000
Exercise price: $1.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.